Actively Recruiting
Define Predictors for Posttransplant Diabetes Mellitus Study
Led by University Hospital, Antwerp · Updated on 2024-06-03
330
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Antwerp
Lead Sponsor
U
Universitair Ziekenhuis Brussel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary aim of this prospective, multicentre study is to develop an accurate and convenient tool to predict the risk of PTDM at 3 months post-transplant, based on information on the day of transplantation (day 0). In order to create such model, we will start by identifying individual predictor variables at the day of transplantation and subsequently explore the optimal combination of these predictors in multivariable models. Secondary objectives include: * Compare the performance of the model based on predictor variables at day 0 with existing models for prediction of PTDM (Chakkera, San Antonio Diabetes Prediction Model and Framingham Offspring Study Diabetes Mellitus algorithm) * Explore the glucose level evolution during the first 2 weeks after transplantation using continuous glucose monitoring, and its relationship with baseline patient characteristics and immunosuppressant drug use. * Evaluate the added value of incorporating information on glucose levels in the first and second weeks post-transplant to improve the PTDM prediction model. * Identify predictors for early post-transplant hyperglycemia (first 2 weeks post-transplantation) * Explore the correlation between early post-transplant hyperglycemia (fasting glycemia, pre-dinner glycemia) and PTDM at 3 months
CONDITIONS
Official Title
Define Predictors for Posttransplant Diabetes Mellitus Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (≥18 years) with end stage kidney disease undergoing kidney transplantation with a deceased or living donor
- Signed informed consent
- Initial therapy with at least tacrolimus and corticosteroids
You will not qualify if you...
- Patients with a diagnosis of diabetes mellitus (either type 1 or type 2) prior to kidney transplantation
- Treatment with GLP1-RA for weight losing purposes
- Patients receiving a multi-organ transplantation
- ABO incompatibility
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZA
Edegem, Antwerpen, Belgium, 2650
Actively Recruiting
Research Team
Y
Yassine Laghrib, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here